The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement
@article{Cox2004TheRO, title={The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement}, author={T. Cox and J. Aerts and G. Andria and M. Beck and N. Belmatoug and B. Bembi and R. Chertkoff and S. vom Dahl and D. Elstein and A. Erikson and M. Giralt and R. Heitner and C. Hollak and M. Hřeb{\'i}{\vc}ek and S. A. Lewis and A. Mehta and G. Pastores and A. Rolfs and M. S. S{\'a} Miranda and A. Zimran}, journal={Journal of Inherited Metabolic Disease}, year={2004}, volume={26}, pages={513-526} }
N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of macromolecular substrates that accumulate pathologically in glycosphingolipidoses. Clinical trials of NB-DNJ in patients with Gaucher's disease demonstrate the therapeutic potential of such substrate inhibitors in the glycolipid storage disorders. However, macrophage-targetted enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase… CONTINUE READING
Topics from this paper
222 Citations
Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
- Biology, Medicine
- Molecular therapy : the journal of the American Society of Gene Therapy
- 2019
- 7
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy
- Medicine
- Journal of Inherited Metabolic Disease
- 2010
- 39
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
- Medicine
- Blood cells, molecules & diseases
- 2010
- 80
- PDF
An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
- Medicine
- Core evidence
- 2012
- 27
- PDF
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
- Medicine
- Molecular therapy : the journal of the American Society of Gene Therapy
- 2016
- 41
Substrate reduction therapy of glycosphingolipid storage disorders
- Medicine
- Journal of Inherited Metabolic Disease
- 2006
- 140
Review of miglustat for clinical management in Gaucher disease type 1
- Medicine
- Therapeutics and clinical risk management
- 2008
- 51
- PDF
N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
- Chemistry, Medicine
- Molecular genetics and metabolism
- 2016
- 8
References
SHOWING 1-10 OF 61 REFERENCES
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
- Medicine
- The Lancet
- 2000
- 669
Substrate reduction therapy of glycosphingolipid storage disorders
- Medicine
- Journal of Inherited Metabolic Disease
- 2006
- 140
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
- Biology, Medicine
- The Journal of biological chemistry
- 1994
- 402
- PDF
Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources
- Medicine
- Annals of Internal Medicine
- 1995
- 404
Failure of Alglucerase Infused into Gaucher Disease Patients to Localize in Marrow Macrophages
- Medicine
- Molecular medicine
- 1995
- 27
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
- Biology, Medicine
- Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
- 1995
- 43
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
- Medicine
- The New England journal of medicine
- 1991
- 1,083
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
- Medicine
- Journal of acquired immune deficiency syndromes
- 1994
- 89
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
- Medicine
- Blood cells, molecules & diseases
- 2002
- 88